EUVIMEDEUVIMED entdecken
Open Access

SMARCA4 as a support for the differential diagnosis of poorly differentiated lung carcinomas

Martina Panozzi, Greta Alì, Agnese Proietti, Franca Melfi, Carmelina C Zirafa, Marco Lucchi, Gabriella Fontanini

Pathologica · 2023

DOI: 10.32074/1591-951x-847 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathologica, 2023. Verfasst von Martina Panozzi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Neoplasms, Glandular and Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Among non-small cell lung cancers (NSCLCs), sarcomatoid carcinomas account for 3%. They are rare tumours with a poor prognosis, classified into three subgroups, namely pleomorphic carcinoma, pulmonary blastoma and carcinosarcoma. In the 5th edition of WHO Classification of Thoracic Tumours more space is given to SMARC4-deficient lung cancers. Although studies on SMARCA4-deficient lung tumours are limited, a small percentage of SMARCA4 loss is present within NSCLCs. This finding is clinically relevant, as the loss of the SMARCA4 gene is associated with a worse prognosis. In our study, we analysed the presence of the main catalytic subunit of the SMARCA4 gene, the BRG1 protein, in 60 sarcomatoid lung tumours. The results of our study show that 5.3% of sarcomatoid carcinomas have BRG1-loss in tumour cells, proving that a non-negligible amount of lung sarcomatoid carcinomas are SMARCA4-deficient. These data open the debate on the necessity of including the detection of SMARCA4 within a standardised immunohistochemical panel.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasms, Glandular and EpithelialCarcinoma, Non-Small-Cell LungLung NeoplasmsCarcinomaHumansDiagnosis, DifferentialLungDNA HelicasesNuclear ProteinsTranscription Factors

Stichwörter der Autor:innen

BRG1NSCLCSMARCA4pleomorphic lung cancersarcomatoid lung cancer

Substanzen

SMARCA4 protein, humanDNA HelicasesNuclear ProteinsTranscription Factors

Autor:innen und Institutionen

  • Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
  • Unit of Pathological Anatomy, University Hospital of Pisa, Pisa, Italy.
  • Multispecialty Centre for Surgery, Minimally Invasive and Robotic Thoracic Surgery, University Hospital of Pisa, Pisa, Italy.
  • Unit of Thoracic Surgery, University Hospital of Pisa, Italy.

Zitieren

APA

Panozzi, M., Alì, G., Proietti, A., Melfi, F., Zirafa, C. C., Lucchi, M., & Fontanini, G. (2023). SMARCA4 as a support for the differential diagnosis of poorly differentiated lung carcinomas. Pathologica. https://doi.org/10.32074/1591-951x-847

Vancouver

Panozzi M, Alì G, Proietti A, Melfi F, Zirafa CC, Lucchi M, et al. SMARCA4 as a support for the differential diagnosis of poorly differentiated lung carcinomas. Pathologica. 2023. doi:10.32074/1591-951x-847

BibTeX
@article{Panozzi2023,
  author = {Panozzi, Martina and Alì, Greta and Proietti, Agnese and Melfi, Franca and Zirafa, Carmelina C and Lucchi, Marco and Fontanini, Gabriella},
  title = {SMARCA4 as a support for the differential diagnosis of poorly differentiated lung carcinomas},
  journal = {Pathologica},
  year = {2023},
  doi = {10.32074/1591-951x-847}
}
Kostenlos starten →